Gastroenterology Phase 3 Deal Benchmarks — Ex-US

Understanding Gastroenterology Deal Benchmarks at Phase 3

Phase 3 Gastroenterology licensing deals in Ex-US territory command a median upfront payment of $693M, with values ranging from $441M at the low end to $1.0B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the gastroenterology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.8B to $3.0B, with a median of $2.4B. Royalty rates for gastroenterology assets at this stage typically fall between 8.4% and 15.2% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.